Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GU 2022 | Do we have a bladder-intact cure for muscle invasive bladder cancer?

Alexandre Zlotta • 18 Feb 2022
ASCO GU 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Alexandre R. Zlotta, MD, PhD, Mount Sinai Hospital and University of Toronto, Toronto, Canada, discusses how far away we are from a bladder-intact cure for muscle-invasive bladder cancer. Currently, bladder-sparing trimodality therapy is often used only for patients who are not eligible for surgery, making it difficult to compare the outcomes of the two treatment options. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Alexandre Zlotta

1:51
Radical cystectomy vs. trimodality therapy for muscle-invasive bladder cancer
Alexandre Zlotta • 18 Feb 2022
1:24
Bladder-sparing treatment vs. radical cystectomy for patients with urothelial carcinoma
Alexandre Zlotta • 18 Feb 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals